Scarica l'app Stockscreener
85.39
0.15%
-0.13
Dopo l'orario di chiusura:
84.00
-1.39
-1.63%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Ani Pharmaceuticals Inc Borsa (ANIP) Ultime notizie
40 Under 40: Kevin Chan, ANI Pharmaceuticals - Medical Marketing and Media
Breakout Move: Does ANI Pharmaceuticals Inc stock have upside surprise potential - baoquankhu1.vn
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Mizuho Markets Americas LLC - MarketBeat
Aug Setups: What is the next catalyst for SEALPRAQuarterly Earnings Report & Technical Pattern Based Signals - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Invests $1.60 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Is Up 11.2% After Raising 2026 Revenue Outlook And Rare Disease Hiring Plan – Has The Bull Case Changed? - Sahm
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? - Eastern Progress
ANIP Stock Rises 7% in a Week: Here's What You Should Know - Eastern Progress
Guggenheim Reaffirms Their Buy Rating on ANI Pharmaceuticals (ANIP) - The Globe and Mail
SG Americas Securities LLC Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Is Up 7.0% After Raising 2026 Revenue Outlook and Expanding Rare Disease Team - Yahoo Finance
Insider Sell Alert: Meredith Cook Sells Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals’ Cook sells $42,165 in stock By Investing.com - Investing.com Australia
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Stock - MarketBeat
Ani Pharmaceuticals’ Cook sells $42,165 in stock - Investing.com
ANI Pharmaceuticals Targets $1B+ 2026 Revenue as Rare Disease Pivot Accelerates, Cortrophin Leads Growth - Yahoo Finance
ANI Pharmaceuticals (ANIP) Stock Dips on Profit-Taking After 2026 GuidanceNews and Statistics - IndexBox
ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why - Finviz
ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance (NASDAQ:ANIP) - Seeking Alpha
Stocks making big moves yesterday: OneMain, Nextpower, ANI Pharmaceuticals, Akamai Technologies, and Lemonade - The Globe and Mail
Growth Review: Can ANI Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Performance Recap & Stepwise Trade Signal Implementation - Bộ Nội Vụ
Fund Flows: Why ANI Pharmaceuticals Inc stock remains undervaluedEarnings Risk Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
ANI Pharmaceuticals, Inc. (ANIP) Investor Outlook: Exploring a 29.52% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Decker Retirement Planning Inc. Boosts Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals expects over $1 billion in 2026 revenue By Investing.com - Investing.com Nigeria
Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today - Finviz
The Sun: Local News, Sports and Things to DoWhy ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today - FinancialContent
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap UpTime to Buy? - MarketBeat
Ani Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance - MarketBeat
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities - The Manila Times
ANI Pharmaceuticals expects over $1 billion in 2026 revenue - Investing.com
ANI Pharma is building a 90-person rare disease team for gout flares in 2026 - Stock Titan
ANI Pharmaceuticals (ANIP) Valuation Check After Robust 2025 Results And Raised Guidance - Sahm
How ANI Pharmaceuticals Inc. stock performs in weak economyWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - Улправда
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 6.3%Time to Sell? - MarketBeat
Momentum Shift: How ANI Pharmaceuticals Inc. stock performs in weak economyTrade Entry Summary & High Return Trade Guides - Улправда
How ANI Pharmaceuticals Inc. (BSFA) stock trades pre earningsPortfolio Performance Report & Fast Momentum Entry Tips - Улправда
Do Strong 2025 Rare Disease Results Reshape the Bull Case for ANI Pharmaceuticals (ANIP)? - Sahm
How ANI Pharmaceuticals Inc. stock reacts to global recession fears2025 Growth vs Value & Reliable Breakout Stock Forecasts - ulpravda.ru
Is ANI Pharmaceuticals Inc. (BSFA) stock a defensive play amid uncertainty2025 EndofYear Setup & Expert Verified Stock Movement Alerts - ulpravda.ru
What earnings margins imply for ANI Pharmaceuticals Inc. (BSFA) stockJuly 2025 Spike Watch & Consistent Return Investment Signals - ulpravda.ru
ANI Pharmaceuticals (NASDAQ:ANIP) Lowered to "Hold" Rating by Zacks Research - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Nasdaq Today Specialty Pharma Focus - Kalkine Media
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Is ANI Pharmaceuticals (ANIP) Price Justified After Updated 2025 Revenue Guidance? - Yahoo Finance
ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? - Your Wyoming Link
ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis: A Healthcare Gem with 38.89% Upside Potential - DirectorsTalk Interviews
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
3.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):